(Q36627279)

15 August 2017

1 reference

title

Ranibizumab: treatment in patients with neovascular age-related macular degeneration (English)

1 reference

15 August 2017

Dante J Pieramici

1

1 reference

15 August 2017

Robert L Avery

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

Expert Opinion on Biological Therapy

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1237-1245

1 reference

Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Vascular endothelial growth factor is a secreted angiogenic mitogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Pegaptanib for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Antibody humanization using monovalent phage display

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Pegaptanib: in exudative age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

21 January 2018

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.11.1237

10.1517/14712598.6.11.1237

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference